… associated with workforce reduction ($0.05) and transactions ($0.02) related to Athena Diagnostics and Celera Corporation . The year-ago period also witnessed the impact of severe weather ($0.05) and restructuring charges Complete …
… DGX also announced plans to purchase Celera Corporation CRA for $344 million in cash. Because we ..... Quest's desire to go after targets like Celera . Nonetheless, we have long been lukewarm on Celera , which has had difficulty achieving …
Celera ( CRA ) now +27.3% to $7.98 after announcing earlier this morning it was being bought by Quest Diagnostics ( DGX ) for $8/share. Post your comment!
Quest Diagnostics ( DGX ) to buy Celera ( CRA ) in an $8/share deal valuing Celera at $344M. Quest says the deal "will further strengthen our leadership position in molecular diagnostics discovery and development and drive sustainable revenue growth." ( PR ) Post your comment!
… than have her rivals . But Xie has gotten a lot of mileage from her holdings ; names such as Alexion Pharmaceuticals ALXN and Celera CRA are among the fund's biggest winners over the past five years . Xie's willingness to make large industry bets carries …
We are no longer providing equity research on Celera Corporation CRA . We provide broad coverage of more than 1,800 companies across 91 industry groups and adjust our coverage as necessary based on client demand and investor interest.
We are no longer providing equity research on Celera Corporation CRA . We provide broad coverage of more than 1,800 companies across 91 industry groups and adjust our coverage as necessary based on client demand and investor interest.
We're placing our fair value estimate for Celera CRA under review after the company warned on second-quarter results and was forced into a downsizing.
We're transferring coverage of Celera CRA to a new analyst and will publish a new report shortly.
… Applera's possible move to split its Applied Biosystems and Celera CRA units into two separate companies. The firm expects to make ..... shareholders. By separating Applied Biosystems from loss-generating Celera , we think Applera will unlock value for shareholders.